Compare AGO & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGO | LIVN |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2003 | 2015 |
| Metric | AGO | LIVN |
|---|---|---|
| Price | $81.83 | $63.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $101.67 | $72.43 |
| AVG Volume (30 Days) | 254.4K | ★ 858.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 49.34 | N/A |
| EPS | ★ 10.26 | N/A |
| Revenue | ★ $1,110,000,000.00 | N/A |
| Revenue This Year | $3.06 | $9.43 |
| Revenue Next Year | N/A | $6.85 |
| P/E Ratio | $7.96 | ★ N/A |
| Revenue Growth | ★ 27.29 | N/A |
| 52 Week Low | $74.09 | $32.48 |
| 52 Week High | $92.40 | $71.58 |
| Indicator | AGO | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 48.58 |
| Support Level | $79.57 | $61.80 |
| Resistance Level | $83.39 | $65.25 |
| Average True Range (ATR) | 1.54 | 1.86 |
| MACD | -0.28 | 0.07 |
| Stochastic Oscillator | 20.95 | 86.84 |
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.